REFERENCES
- German P, Warren D, West S, Hui J, Kearney BR Pharma-cokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010;55(3):323–329.
- Shimura K, Kodama E, Sakagami Y, et al. Broad antiret-roviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008 ;82 (2):764–774.
- McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy. Antiviral Res. 2010;85(1):101–118.
- Abram ME, Hluhanich RM, Goodman DD, et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fit-ness. Antimicrob Agents Chemother. 2013;57(6):2654–2663.
- Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: A novel pharmaco-kinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010;87(3):322–329.
- DeJesus E, Rockstroh J, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazana-vir plus co-formulated emtricitabine and tenofovir diso-proxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379:2429–2438.
- Rockstroh JK, Dejesus E, Henry K, et al. A randomized, double-blind comparison of co-formulated elvitegravir/ cobicistat/emtricitabine/tenofovir versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62(5): 483–486.
- Clumeck N, Molina JM, Henry K, et al. A randomized, dou-ble-blind comparison of single-tablet regimen elvitegravir/ cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treat-ment of HIV-1 infection: Analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e121–124.
- Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Che-mother. 2000;44:920–928.
- Johnson VA, Calvez V, Gunthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antiviral Med. 2011;19(4):156–164.
- Lathouwers E, De Meyer S, Dierynck I, et al. Virologi-cal characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. Antivir Ther. 2011;16(1):99–108.
- Molina JM, Lamarca A, Andrade-Villanueva J, et al. Effi-cacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012;12:27–35.
- White K, Kulkarni R, Abram M, et al. Longitudinal resis-tance anaylsis of the phase 3 EVG/COBI/FTC/TDF studies. Presented at: 12th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance; 2014; Barcelona, Spain. Poster 0_12.
- Xu L, Liu H, Murray BP, et al. Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Medicinal Chem Lett. 2010;1:209–213.
- Los Alamos National Laboratory. HIV molecular immunol-ogy: Maps of CTUCD8+ epitope locations plotted by pro-tein. http://www.hiv.lanl.gov/content/immunology/maps/ctl/ctl.pdf. Accessed February 13, 2014.
- Brumme ZL, John M, Carlson JM, et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One. 2009;4(8):e6687.
- Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother. 2007;59(6):1047–1056.
- Sax PE, DeJesus E, Mills A, et al. Co-formulated elvite-gravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012 ;379(9835):2439–2448.
- Tivicay (dolutegravir) tablets for oral use. US prescribing information. Research Triangle Park, NC: GlaxoSmithKline. Revised August 2013.
- Eron JJ, Clotet B, Durant J, et al. Safety and effi-cacy of dolutegravir in treatment-experienced sub-jects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013;207(5):740–748.